Skip to content

Probiotix Health PLC - Result of AGM and Notice of Trading Update


Announcement provided by

ProBiotix Health Plc · PBX

27/06/2025 12:35

Probiotix Health PLC - Result of AGM and Notice of Trading Update
RNS Number : 7905O
Probiotix Health PLC
27 June 2025
 

27 June 2025

                                                                                                                                 

ProBiotix Health plc

("ProBiotix Health" or the "Company" or, together with its subsidiary, the "Group")

 

Result of AGM and Notice of Trading Update

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that at the AGM held earlier today, all resolutions were duly passed.

 

The full voting results will be available on the Company's website in due course at www.probiotixhealth-ir.com.

 

Momentum in the business continues to be strong, buoyed by increasing demand for our products. A trading update for the first six months of the current financial year will be issued on 15 July 2025.

 

 

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

 

investors@probiotixhealth.com

Steen Andersen, Chief Executive Officer

Miles Nolan, Investor Relations

 



Peterhouse Capital Limited

Aquis Corporate Adviser and Broker

Tel: 020 7469 0930

 

 

Mark Anwyl

Duncan Vasey


 


This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

Notes to Editors:

 

ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix Health has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

 

The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXPKOBNDBKDBAB]]>

View more ...

PBX announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2025. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal